Edwards Lifesciences’ EW stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the consensus of $1.49 billion and within the m ...

Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday.Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus expectations of $1.488 billion.Edwards Lifesciences affirmed FY2025 adjusted EPS guidance of $2.40-$2.50 and raised FY2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion.“We are pleased to ...

Key Takeaways EW posted Q2 EPS of $0.67 and sales of $1.53B, beating estimates and growing 8.1% and 11.7% YoY, respectively.EW saw strong growth in TAVR and TMTT, driven by U.S. trial data, device adoption and global market shifts.Edwards Lifesciences raised 2025 guidance despite margin pressure from higher costs and expenses.Edwards Lifesciences Corporation (EW) reported second-quarter 2025 adjusted earnings per share (EPS) of 67 cents, which surpassed the Zacks Consensus Estimate by 8.1%. The figure incre ...

Edwards Lifesciences (EW) reported $1.53 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.1%. EPS of $0.67 for the same period compares to $0.70 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.49 billion, representing a surprise of +2.85%. The company delivered an EPS surprise of +8.06%, with the consensus EPS estimate being $0.62.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Edwards Lifesciences (EW) Q2 2025 Earnings Call July 24, 2025 05:00 PM ET Company ParticipantsMark Wilterding - SVP - IR & Global FinanceBernard Zovighian - CEOScott Ullem - Corporate VP & CFOLarry Wood - Corporate VP, Transcatheter Aortic Valve ReplacementDan Lippis - Corporate Vice PresidentTravis Steed - MD - Equity ResearchDavid Roman - Managing DirectorDaveen Chopra - Corporate Vice President - Transcatheter Mitral & Tricuspid TherapiesMatt Taylor - Managing DirectorAnthony Petrone - MD - Equity Resear ...

Edwards Lifesciences (EW) Q2 2025 Earnings Call July 24, 2025 05:00 PM ET Speaker0Greetings, and welcome to the Edwards Lifesciences Second Quarter twenty twenty five Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Mark Wilterding, Senior Vice President, Global Finance.Thank you. You may begin.Speaker1Thank you ...

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) [Second Quarter 2025 Performance](index=1&type=section&id=Second%20Quarter%202025%20Performance) Edwards Lifesciences reported strong double-digit sales growth in the second quarter of 2025, with total sales reaching $1.53 billion, an 11.9% increase (10.6% adjusted), this growth was driven by strong performance across all product groups, particularly TMTT which grew over 60%, and adjusted EPS for the quarter was $0.67 Q2 2025 Key Financial Metrics | Metric | Value | Growth (YoY) | Adjusted Value | Adjusted Growth (YoY) | | :--- | :--- | :--- | :--- | :--- | | **Total Sales** | $1.53 billion | 11.9% | $1.53 billion | 10.6% | | **TAVR Sales** | $1.1 billion | 8.9% | $1.13 billion | 7.8% (Constant Currency) | | **TMTT Sales** | $134.5 million | 61.9% | $133.0 million | 57.1% | | **Diluted EPS** | $0.57 | - | $0.67 | - | - Key operational and clinical achievements in Q2 include: - The SAPIEN platform became the only TAVR approved for asymptomatic patients in both the U.S. and Europe - 10-year data from the PARTNER II study confirmed the long-term durability of Edwards TAVR - The SAPIEN M3 system received CE Mark approval, enhancing the TMTT portfolio[4](index=4&type=chunk) [Full Year 2025 Outlook](index=1&type=section&id=Full%20Year%202025%20Outlook) Buoyed by strong first-half performance, the company has raised its full-year 2025 guidance, projecting total sales growth of 9-10% (up from 8-10%) and increased TAVR sales growth, with adjusted EPS now expected at the high end of the $2.40 to $2.50 range - CEO Bernard Zovighian expressed confidence in the full-year outlook, citing better-than-expected first-half performance and multiple catalysts across the product portfolio[3](index=3&type=chunk) Updated Full-Year 2025 Guidance | Metric | Previous Guidance | Updated Guidance | | :--- | :--- | :--- | | **Total Sales Growth** | 8-10% | 9-10% | | **Total Sales** | - | $5.9B - $6.1B | | **TAVR Sales Growth** | 5-7% | 6-7% | | **TAVR Sales** | - | $4.3B - $4.5B | | **Adjusted EPS** | $2.40 - $2.50 | High-end of $2.40 - $2.50 | - For the third quarter of 2025, the company projects total sales between $1.46 and $1.54 billion and adjusted EPS of $0.54 to $0.60[17](index=17&type=chunk) [Business Segment Performance](index=2&type=section&id=Business%20Segment%20Performance) [Transcatheter Aortic Valve Replacement (TAVR)](index=2&type=section&id=Transcatheter%20Aortic%20Valve%20Replacement%20(TAVR)) The TAVR segment reported sales of $1.1 billion, growing 8.9% (7.8% constant currency) in Q2, driven by continued SAPIEN technology adoption, a renewed focus on timely severe aortic stenosis treatment in the U.S., and market share gains in Europe following a competitor's exit TAVR Q2 2025 Performance | Metric | Value | Growth (YoY) | Constant Currency Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $1.1 billion | 8.9% | 7.8% | - In the U.S., the EARLY TAVR trial data is encouraging more timely treatment of patients with severe aortic stenosis (AS) - In Europe, a competitor's exit led to a rebalancing of market share, modestly benefiting Edwards' sales - In Japan, TAVR sales grew in the mid-single digits, an improvement from the previous quarter[6](index=6&type=chunk)[7](index=7&type=chunk) [Transcatheter Mitral and Tricuspid Therapies (TMTT)](index=2&type=section&id=Transcatheter%20Mitral%20and%20Tricuspid%20Therapies%20(TMTT)) The TMTT segment achieved impressive growth, with sales reaching $134.5 million (61.9% year-over-year increase), fueled by strong PASCAL technology adoption, a successful EVOQUE system launch, and portfolio strengthening via CE Mark approval for the SAPIEN M3 mitral valve replacement system TMTT Q2 2025 Performance | Metric | Value | Growth (YoY) | Adjusted Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $134.5 million | 61.9% | 57.1% | - Strong adoption of PASCAL technology continues in new and existing centers - The EVOQUE system's commercial launch is progressing well in the U.S. and Europe, with high demand - The SAPIEN M3 mitral valve system received CE Mark approval in Q2, receiving positive early clinician feedback[9](index=9&type=chunk)[10](index=10&type=chunk) [Surgical](index=2&type=section&id=Surgical) The Surgical segment posted Q2 sales of $267 million (7.7% increase), supported by positive global procedure trends for its premium RESILIA tissue portfolio, including INSPIRIS, MITRIS, and KONECT technologies, with the KONECT aortic valved conduit also receiving CE Mark approval in Europe during the quarter Surgical Q2 2025 Performance | Metric | Value | Growth (YoY) | Constant Currency Growth (YoY) | | :--- | :--- | :--- | :--- | | **Sales** | $267 million | 7.7% | 6.8% | - The company's KONECT aortic valved conduit received CE Mark approval in Europe during the second quarter[12](index=12&type=chunk) [Detailed Financial Results](index=3&type=section&id=Detailed%20Financial%20Results) [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2025, net sales increased to $1.53 billion from $1.37 billion, gross profit rose to $1.19 billion despite a gross margin decline to 77.5%, and operating income increased to $411.2 million, though net income from continuing operations decreased to $335.9 million primarily due to higher income taxes and an impairment loss Q2 Statement of Operations (in millions) | Account | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | **Net sales** | $1,532.2 | $1,369.4 | +11.9% | | **Gross profit** | $1,187.8 | $1,093.9 | +8.6% | | **Operating income, net** | $411.2 | $366.5 | +12.2% | | **Net income from continuing operations** | $335.9 | $364.0 | -7.7% | [Operating Expenses and Margins](index=3&type=section&id=Operating%20Expenses%20and%20Margins) The Q2 gross profit margin was 77.5% (down from 79.9%) due to manufacturing expenses and foreign exchange, while SG&A expenses rose to $502 million (32.8% of sales) and R&D expenses were $276 million (18.0% of sales), reflecting strategic investment prioritization, resulting in an adjusted operating margin of 28.2% Q2 2025 Key Margins and Expenses | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | **Gross Profit Margin** | 77.5% | 79.9% | | **SG&A (% of Sales)** | 32.8% | 32.7% | | **R&D (% of Sales)** | 18.0% | 19.8% | | **Operating Profit Margin** | 26.8% | 26.8% | | **Adjusted Operating Profit Margin** | 28.2% | 27.4% | - The year-over-year decrease in gross margin was driven by additional manufacturing expenses for new therapies and foreign exchange effects[13](index=13&type=chunk) [Balance Sheet and Cash Position](index=3&type=section&id=Balance%20Sheet%20and%20Cash%20Position) As of June 30, 2025, Edwards Lifesciences maintained a strong liquidity position with approximately $3 billion in cash and cash equivalents and total debt of approximately $600 million Key Balance Sheet Items (as of June 30, 2025) | Item | Amount | | :--- | :--- | | **Cash and cash equivalents** | ~$3 billion | | **Total debt** | ~$600 million | [Non-GAAP Reconciliation](index=6&type=section&id=Non-GAAP%20Reconciliation) The company uses non-GAAP measures to exclude items like certain litigation expenses, amortization, separation costs, and impairment losses, providing a clearer view of core operational performance, which for Q2 2025 resulted in a non-GAAP adjusted EPS of $0.67 from a GAAP diluted EPS of $0.57 - Management uses non-GAAP measures for internal decision-making and to enhance comparability with industry peers by excluding items that do not reflect core operational activities[27](index=27&type=chunk)[28](index=28&type=chunk) Q2 2025 GAAP to Non-GAAP EPS Reconciliation | Description | Per Share Amount | | :--- | :--- | | **GAAP Diluted EPS from Continuing Operations** | **$0.57** | | Certain litigation expenses | $0.03 | | Separation costs | $0.01 | | Loss on impairment | $0.06 | | **Adjusted Diluted EPS** | **$0.67** | [Sales by Product Group and Region](index=9&type=section&id=Sales%20by%20Product%20Group%20and%20Region) On a constant currency basis for Q2 2025, TAVR grew 7.8%, TMTT grew 57.1%, and Surgical grew 6.8%, while regionally, the U.S. saw 10.1% adjusted growth and sales outside the U.S. grew 11.3% on a constant currency basis, led by strong performance in the Rest of World category Q2 2025 Constant Currency Growth (YoY) | Category | Constant Currency Growth Rate | | :--- | :--- | | **Product Groups** | | | TAVR | 7.8% | | TMTT (Adjusted) | 57.1% | | Surgical | 6.8% | | **Regions (Adjusted)** | | | United States | 10.1% | | Europe | 9.6% | | Japan | 4.2% | | Rest of World | 19.5% |

Core Viewpoint - Edwards Lifesciences Corp. is set to report its second-quarter 2025 results on July 24, with expectations of revenue and earnings declines compared to the previous year [1][2]. Q2 Estimates - The Zacks Consensus Estimate for revenues is $1.49 billion, indicating an 8.9% decline from the prior year's figure [2]. - The estimate for net earnings is 62 cents per share, reflecting an 11.4% decrease from the year-ago reported figure [2]. Estimate Revision Trend - Earnings estimates have remained unchanged at 62 cents per share over the past 60 days, indicating stability in expectations ahead of the earnings announcement [3]. Factors at Play - The Transcatheter Aortic Valve Replacement (TAVR) segment is expected to perform well in the U.S. due to the SAPIEN 3 Ultra RESILIA platform, with a projected revenue of $1.09 billion, representing a 5.2% year-over-year increase [4][5]. - The TMTT segment is anticipated to show significant growth, with revenues estimated at $130.4 million, a 57.1% improvement from the previous year, driven by the PASCAL and EVOQUE systems [6][8]. Segment Performance - The Surgical Structural Heart segment is expected to report revenues of $263.1 million, suggesting a modest 6.2% rise from the year-ago quarter, supported by the global adoption of the RESILIA portfolio [10][11]. - The commercial launch of the EVOQUE tricuspid replacement system is likely to have progressed well, aided by Medicare coverage [7]. Earnings Whispers - Edwards has an Earnings ESP of 0.00%, indicating no advantage in beating estimates this quarter [12]. - The company currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook compared to other stocks [13].

Wall Street analysts forecast that Edwards Lifesciences (EW) will report quarterly earnings of $0.62 per share in its upcoming release, pointing to a year-over-year decline of 11.4%. It is anticipated that revenues will amount to $1.49 billion, exhibiting a decrease of 8.9% compared to the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

Key Takeaways EW sees strong global uptake in surgical tech and TAVR, with Q1 TAVR sales topping $1 billion again. Edwards' TMTT sales rose 58% in Q1, driven by PASCAL and EVOQUE system adoption across the U.S. and Europe. Macro volatility and foreign exchange headwinds are pressuring EW's operating margin and sales growth.Edwards Lifesciences (EW) is gaining from the robust uptake of its premium surgical technologies. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned fo ...